GlobeNewswire Inc | Nov 16, 2020 07:00AM EST

November 16, 2020

GAITHERSBURG, Md., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual investor conferences:

Jefferies London Virtual Healthcare ConferenceTuesday, November 17, 202011:25 am Eastern Time

Piper Sandler 32nd Annual Virtual Healthcare ConferenceMonday, November 23, 2020 to Thursday, December 3, 2020Fireside chat recording available to conference participants

3rd Annual Evercore ISI Virtual HealthCONx ConferenceWednesday, December 2, 20208:00 am Eastern Time

The sessions will be webcast and can be accessed by visiting the investor relations section of the company's website at www.altimmune.com under Events / Presentations.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Companys diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID), anthrax (NasoShield) and influenza (NasoVAX); an intranasal immune modulating therapeutic for COVID-19 (T-COVID); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visitwww.altimmune.com.

Investor Contacts

Stacey Jurchison Ashley R. RobinsonAltimmune, Investor Relations LifeSci Advisors, LLCPhone: 410-474-8200 617-430-7577sjurchison@altimmune.com arr@lifesciadvisors.com